Phase II clinical trial of bortezomib + pegylated liposomal doxorubicin + dexamethasone followed by thalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone for patients with symptomatic untreated high-risk or primary resistant multiple myeloma
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Bortezomib; Dexamethasone; Doxorubicin liposomal; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 22 Jan 2016 Biomarkers information updated
- 08 Mar 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 15 Jun 2011 Actual end date changed from Dec 2009 to April 2011 as reported by ClinicalTrials.gov.